Omeros Corporation Unternehmenskultur

Dr. Gregory A. Demopulos, M.D., founded Omeros Corporation in June 1994 and has been its Chairman of the Board, Chief Executive Officer and President since June 1994. Dr. Demopulos served as the Chief Financial Officer and Treasurer of Omeros Corporation from January 2009 to August 2013. He served as the Chief Medical Officer at Omeros Corporation from June 1994 to March 2010. He served as an Orthopedic Surgeon with specialized training in hand and microvascular surgery. Dr. Demopulos has been Director of Omeros Corporation and Onconome, Inc. since June 1994. He holds 18 patents in the life sciences with more than 50 additional patent applications. He was the recipient of numerous academic awards and honors. He left academic medicine to found Omeros in June 1994. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University. Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University.

Dr. George A. Gaitanaris, M.D. Ph.D. has been Chief Scientific Officer of Omeros Corporation since January 2012 and serves as its Vice President of Science since August 2006 until January 2012. Dr. Gaitanaris co-founded Nura Inc. in 2003 and served as its Chief Scientific Officer from August 2003 to August 2006. He co-founded Primal, Inc. and served as its President and Chief Scientific Officer from 2000 to 2003 and served as Staff Scientist at the National Cancer Institute. Dr. Gaitanaris has 25 years in industry and academia, he was one of the first to develop gene knock- out methodologies and characterized the family of G- protein-coupled receptors (GPCRs), which comprise the largest family of genes and are targeted by almost half of all pharmaceuticals on the market. Dr. Gaitanaris received his Ph.D. in cellular, molecular and Biophysical Studies and his M.Ph. and M.A. from Columbia University and completed post doctoral work at Princeton University. He holds an M.D. from the Aristotelian University of Greece.

Ms. Marcia S. Kelbon, Esq., J.D., M.S., has been General Counsel of Omeros Corporation since October 2001. Ms. Kelbon has been the Secretary of Omeros Corporation since September 2007. Ms. Kelbon has been the Vice President of Patent of Omeros Corporation since October 2001. She joined Omeros in 2001. She served as a Partner with Christensen O???Connor Johnson & Kindness, PLLC, where she specialized in U.S. and international intellectual property procurement, management, licensing and enforcement issues. While at Christensen O???Connor, Ms. Kelbon played a key role in drafting and prosecuting Omeros??? core patents. She is a Member of the Washington State Bar. She holds an AV rating from Martindale-Hubbell and was designated as a Super Lawyer by Washington Law and Politics in 2005. Ms. Kelbon received her J.D. and her M.S. in chemical engineering from the University of Washington and her B.S. from The Pennsylvania State University.

Mr. Leonard M. Blum has been the Chief Business and Commercial Officer at Omeros Corporation since April 2016. Mr. Blum served as the Chief Commercial Officer and Senior Vice President of Theravance Biopharma, Inc. since 2007 until March 2016. Mr. Blum has over 28 years of marketing and sales leadership experience in the biotechnology and pharmaceutical industries. He served as the Chief Commercial Officer and Senior Vice President of Theravance Inc. (now known as Innoviva, Inc.) from July 31, 2007 to September 30, 2014. Prior to Theravance, he served as Senior Vice President, Sales & Marketing of ICOS Corporation from May 2005 to July 2007. He joined ICOS as Vice President, Marketing in June 2000 and served as its Vice President, Sales & Marketing since January 2001. From 1987 to June 2000, Mr. Blum held positions of increasing responsibility in marketing and sales management at Merck & Co., Inc. in both U.S. and international markets. From August 1997 to June 2000, Mr. Blum served in various capacities for Merck Sharp & Dohme Israel (Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme), including Marketing Director and Business Unit Director. He joined Merck and Co. in 1987, served in several positions in the United States and led sales and marketing teams in Germany, Israel and Switzerland. His previous experience includes service as an officer in the United States Army Special Forces and a Corporate Financial Analyst with the Investment Banking Division at Shearson Lehman American Express, a financial services company. He was a Fulbright Fellow in international finance at The University of Zurich. Mr. Blum received his M.B.A. from the Stanford Graduate School of Business and his A.B. in Economics, magna cum laude, from Princeton University.

Dr. Catherine A. Melfi, also known as Cathy, Ph.D., has been the Chief Regulatory Officer at Omeros Corporation since April 2016. Dr. Melfi served as Vice President of Regulatory Affairs & Quality Systems at Omeros Corporation since October 2012. 2016. Dr. Melfi has 17 years of experience in the pharmaceutical industry and 11 years of experience in academia, covering the fields of regulatory affairs and health economics and outcomes research. She has provided strategic and technical input into the development and commercialization of pharmaceutical products across all phases of development. She served at Eli Lilly and Company, where she held technical and leadership roles of increasing scope and responsibility in Global Health Outcomes and Regulatory Affairs. Dr. Melfi held various faculty and staff positions at Indiana University, including appointments in their Economics Department, in the School of Public and Environmental Affairs and in the Indiana University School of Medicine. Dr. Melfi received her Ph.D. in Economics from the University of North Carolina - Chapel Hill and B.S. in Economics from John Carroll University.

Dr. J. Steven Whitaker, also known as Steve, M.D., J.D. has been the Chief Medical Officer of Omeros Corporation since March 2010. Dr. Whitaker served as Vice President Of Clinical Development of Omeros Corporation since March 2010. Dr. Whitaker served as Chief Medical Officer and Vice President, Clinical Development of Allon Therapeutics, Inc. from May 2008 to March 26, 2010. He managed the clinical development and medical affairs related to Allon's expanding program of clinical trials, including interactions with prospective pharmaceutical company partners, regulatory authorities, trial investigators, physicians and patients. He has experience in managing a joint venture. At ICOS, he held roles of increasing responsibility in clinical research and medical affairs and served as divisional vice president, clinical research as well as medical director of the Cialis global product team. He served as Division Vice-President, Clinical Research of ICOS Corporation in Seattle since May 1994 until it was acquired by Eli Lilly and Company in May 2007. From August 2007 to May 2008, he served as a medical consultant to Accelerator Corporation. He held a number of roles of increasing responsibility in clinical research and medical affairs after joining ICOS in 1994. His achievements include filing with the United States Food and Drug Administration an Investigational New Drug application for approval to start clinical trials and a New Drug Application for marketing approval for the same product. Dr. Whitaker received an M.D. (with highest distinction) from the Indiana University School of Medicine, a J.D. (with highest distinction) from the University Of Washington School Of Law and a Bachelor of Science in physics and mathematics from Butler University.

Tim Duffy serves as the Vice President, Business Development of Omeros Corporation. Tim started at Omeros Corporation in Mar of 2010. Tim currently resides in the Greater Seattle Area.

Chris Bral serves as the Vice President, Nonclinical Development and Project Management of Omeros Corporation. Chris started at Omeros Corporation in October of 2015. Chris currently resides in the Greater Seattle Area.